Switching from Antipsychotic Polypharmacy to Monotherapy in Schizophrenia: Risks and Benefits
Antipsychotic (AP) polypharmacy is common in psychiatric practice, despite concerns about its risks and questions regarding its effectiveness.
Antipsychotic (AP) polypharmacy is common in psychiatric practice, despite concerns about its risks and questions regarding its effectiveness.
The use of combination pills aims to enhance treatment effectiveness while minimizing side effects, especially hypogylcemia.
Two recent studies have shed additional light on caffeine use and smoking in patients with serious mental illness (SMI).
Symptomatic relapse is common in schizophrenia and related psychotic disorders, and one of the most common contributors to relapse is poor medication adherence.